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Abstract
Objective: The ALSFRS-R is limited by multidimensionality, which originates from the summation of various subscales.
This prevents a direct comparison between patients with identical total scores. We aim to evaluate how multidimension-
ality affects the performance of the ALSFRS-R in clinical trials. Methods: We simulated clinical trial data with different
treatment effects for the ALSFRS-R total score and its subscales (i.e. bulbar, fine motor, gross motor and respiratory).
We considered scenarios where treatment reduced the rate of ALSFRS-R subscale decline either uniformly (i.e. all sub-
scales respond identically to treatment) or non-uniformly (i.e. subscales respond differently to treatment). Two main
analytical strategies were compared: (1) analyzing only the total score or (2) utilizing a subscale-based test (i.e. alterna-
tive strategy). For each analytical strategy, we calculated the empirical power and required sample size. Results: Both
strategies are valid when there is no treatment benefit and provide adequate control of type 1 error. If all subscales
respond identically to treatment, using the total score is the most powerful approach. As the differences in treatment
responses between subscales increase, the more the total score becomes affected. For example, to detect a 40% reduc-
tion in the bulbar rate of decline with 80% power, the total score requires 1380 patients, whereas this is 336 when using
the alternative strategy. Conclusions: Ignoring the multidimensional structure of the ALSFRS-R total score could have
negative consequences for ALS clinical trials. We propose determining treatment benefit on a subscale level, prior to
stating whether a treatment is generally effective.
Keywords: clinical trials, multidimensionality, ALSFRS-R, therapy, models
Introduction
Regulatory approval of new drugs for ALS requires
conclusive evidence of an improvement in life
expectancy or a slowing in progression rate (1,2). In
general, there are two options as primary outcome
for pivotal ALS clinical trials: (1) endpoints based
on survival time or (2) the revised ALS functional
rating scale (ALSFRS-R). Although each of these
endpoints has its own strengths and weaknesses
(3–5), 82% of the pivotal trials currently use the
ALSFRS-R total score (Table 1) (6).
For an individual patient, the ALSFRS-R total
score is an accurate reflection of disease progres-
sion, where a drop in total score indicates contin-
ued deterioration (5,7,8). The attractiveness of the
total score is its simplicity, consistent change over
time and ability to assess a patient’s functional sta-
tus remotely (9,10). Moreover, the ALSFRS-R
can easily be translated to clinical disease stage
(11,12), providing investigators with the ability to
evaluate when treatments may be most effective
(13). Critical issues arise, however, when
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comparing patients, as two patients with identical
ALSFRS-R total scores may not be comparable
as far as disease stage or prognosis is concerned
(14–16). This issue, often referred to as multidi-
mensionality (14,15), originates from the summa-
tion of various subscales (i.e. bulbar, motor and
respiratory functioning).
Despite this well-known issue, the ALSFRS-R
total score continues to be recommended as a key
efficacy endpoint within current clinical trial guide-
lines (1,2,17). This is not surprising given the
absence of clarity regarding consequences of multi-
dimensionality for clinical trials and the lack of
suitable alternatives. A multidimensional outcome
is essentially a composite endpoint and, like other
composite endpoints (3), treatment effects may
become diluted (18). This is especially true when
outcomes (or subscales) do not respond uniformly
to treatment.
To illustrate, at the design stage of the
Nuedexta trial, existing evidence suggested
enhanced bulbar functioning (19). At the end of
the trial, the investigators indeed concluded bulbar
benefit, a conclusion that would have remained
even if the ALSFRS-R bulbar subscale had been
defined as primary endpoint (p¼0.003). However,
had the investigators used the ALSFRS-R total
score, the trial conclusion would have been futile
(p¼0.25). In this example, it is obvious that only
an outcome that actually measures the targeted
domain should be used, as adding irrelevant end-
points or, in this case, the motor and respiratory
subscales, dilutes the treatment effect.
In most clinical trials, however, it is not known
a priori which subscales will benefit from treat-
ment, or whether all subscales will benefit equally.
In these settings, it remains unclear how multidi-
mensionality of the ALSFRS-R total score, or any
other multidimensional endpoint, may affect trial
conclusions or how best to manage treatment
uncertainty at the design stage. In this study,
therefore, we assess how the ALSFRS-R total
score performs in clinical trials under a variety of
treatment efficacy scenarios, illustrate the pitfalls
and propose a simple alternative strategy to
improve its use in future studies.
Methods
Simulation study
The effect of ALSFRS-R multidimensionality on
clinical trial results was assessed in a simulation
study. We used the PRO-ACT database (version
Dec. 2015) as real-world input for our simulations
(20). All patients provided written informed con-
sent for the collection and use of their data, with
each individual trial being approved by an institu-
tional review board. All data are anonymized and
identifying information has been removed so that
individual studies within PRO-ACT are not trace-
able. We excluded individuals from whom there
was no information on the ALSFRS-R total score
or its subscales. Our primary aim was to simulate
12-month longitudinal patterns. We, therefore,
removed all ALSFRS-R information collected after
13.5 months (allowing for a 6-week collection win-
dow). Four subscales were defined: (1) bulbar;
items 1–3, (2) fine motor; items 4–6, (3) gross
motor; items 7–9 and (4) respiratory functioning;
items 10–12 (7,21).
Linear mixed effects models were used to
model the longitudinal patterns over time on a
subscale level, where the model included a fixed
monthly rate of decline, and a random intercept
and slope per individual. A shared random-effects
structure was modeled per individual to account
Table 1. Overview of currently active and planned pivotal, randomized, placebo-controlled clinical trials on
ClinicalTrials.gov.
Drug Primary efficacy outcome Total sample size Study duration
1. CannTrust CBD Oil ALSFRS-R 30 6.0 months
2. BIIB067 (Tofersen) ALSFRS-R 99 6.5 months
3. Masitinib ALSFRS-R 495 11.1 months
4. Tauroursodeoxycholic acid ALSFRS-R 440 18.0 months
5. Deferiprone CAFS 240 12.0 months
6. Arimoclomol CAFS 231 17.5 months
7. Cu(II)ATSM ALSFRS-R 80 5.5 months
8. MN-166 (Ibudilast) ALSFRS-R 230 12.0 months
9. Ravulizumab ALSFRS-R 354 11.5 months
10. HEALEY Platform trial ALSFRS-R 640 5.5 months
11. MND-SMART ALSFRS-RþSurvival 750 18.0 months
List of compounds was obtained from ClinicalTrials.gov (Q4 2020) by applying the filters: “phase III”,
“interventional”, “active”, “recruiting” and “not yet recruiting”. Information in this table may be incomplete and is
based on publicly available information provided by the study sponsor. Abbreviations: ALSFRS-R¼ revised ALS
functional rating scale; CAFS¼Combined Assessment of Function (i.e., ALSFRS-R) and Survival (4). Platform
trials, effective sample size may deviate per comparison. For example, in the HEALEY platform, four regimes are
evaluated, each with a 3:1 ratio to either active or placebo. This would result in a maximal effective sample size of
120 active vs. 160 placebo per comparison, depending on whether all placebos are incorporated in the analysis.
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for the dependencies and correlations between
subscales; the subscale correlation matrix is pro-
vided in Figure 1. The final (multivariate) model
was used to simulate longitudinal subscale data at
monthly intervals (± 5 days, i.e. SD 0.08) over a
period of 12 months. We added subscale-specific
treatment effects, defined as a % reduction in rate
of decline, in order to simulate different scenarios.
As the total score is simply the sum of the sub-
scales, the treatment response on the total score is
defined as the sum of the subscale responses
(Supplementary methods).
Classical and alternative trial analysis of the
ALSFRS-R
For each scenario, we considered three analytical
strategies, which are discussed below. We assumed
that (a priori) it is not known how treatment will
affect the individual subscales. All analytical strat-
egies have the common objective of identifying a
treatment effect that slows the progression rate
(whether on the total score, or on any of the sub-
scales). Standard practice in clinical trials is to
determine whether the linear rate of disease pro-
gression (i.e. slope) is significantly reduced
compared to a control group (e.g. placebo) (17). A
treatment is considered effective if the p-value for
the slope difference falls below a significance
threshold (e.g. p< 0.05) or, equivalently, when the
confidence interval (e.g. 95%) around the differ-
ence excludes zero (i.e. no difference in slopes).
This decision process is illustrated in Figure 2(A)
for a hypothetical drug with an ineffective
trial result.
In order to address the multidimensional struc-
ture of the ALSFRS-R, a simple alternative strat-
egy might be to evaluate the slope difference in
each subscale individually rather than the differ-
ence in total score. In this framework, a treatment
is considered effective if at least one of the sub-
scales yields a statistically significant difference.
This strategy requires four hypotheses tests and
p-values need to be adjusted to control type I error
(i.e. false-positives) (22). In Figure 2(B), employ-
ing such a strategy would consider the same trial
as in Figure 2(A) as being effective due to the sig-
nificant bulbar effect. Note that for this strategy
there is no particular interest in any individual sub-
scale; as long as at least one subscale yields a stat-
istically significant difference, the treatment is
considered effective.
Figure 1. Correlation matrix of the baseline scores and longitudinal rates of decline within and between subscales. To illustrate, the
rate of decline in fine motor functioning is strongly correlated to the rate of decline in gross motor functioning (Pearson’s r 0.79).
Abbreviations: base¼baseline value at study enrollment; slope¼ rate of decline during follow-up.
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In Figure 2(B), however, the respiratory treat-
ment response is slightly negative. Whether such a
treatment would still be considered effective, des-
pite the positive effect on bulbar function, depends
largely on the extent of the effect. A small negative
effect may still be acceptable (e.g. comparable to
some minor adverse events), while a significant
worsening would be unacceptable. Nonetheless,
according to the decision rule in Figure 2(B), the
respiratory response can be infinitely harmful,
while a treatment would still be classified as super-
ior as long as there is a positive bulbar response.
In Figure 2(C), therefore, we extended the alterna-
tive strategy with a scalable non-inferiority bound-
ary -D. If the confidence interval of the subscale
treatment effect contains the non-inferiority
boundary -D, a potentially harmful subscale effect
cannot be excluded and the treatment is classified
as not non-inferior (23). In this case, the illustrated
trial illustrated would be classified as ineffective as
there is a not non-inferior respiratory effect, despite
the positive bulbar response. The exact value of -D
can be based on a priori expectations and is further
detailed in the Supplementary methods (23).
Comparing analytical strategies
Finally, we used the simulation model to generate
clinical trial data with different treatment efficacy
scenarios, where treatment effects could vary across
subscales (e.g. all subscales respond identically to
treatment vs. subscales respond differently to treat-
ment). On each simulated trial, we applied the three
analytical strategies (Figure 2). Our primary focus
was on empirical power, defined as the proportion
of simulation samples in which the null hypothesis
Figure 2. Illustration of classical and alternative analytical strategies of the ALSFRS-R of the same hypothetical trial; (A) classical
analysis of the mean difference in slopes between the active and placebo arm. A treatment is considered effective if p<0.05. (B)
Alternative analysis where the subscales are tested individually against an adjusted significance threshold. A treatment is considered
effective if any subscale is below the adjusted significance threshold. (C) Similar to B, but with a non-inferiority boundary -D. A
treatment is considered effective if (1) any subscale is below the adjusted one-sided significance threshold and (2) none of the lower
confidence bounds cross the non-inferiority boundary.
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of no treatment effect was rejected. All scenarios
were evaluated using a fixed sample size of 124 per
arm and a 1:1 randomization ratio. The chosen
sample size provides 80% power to detect a 25%
total score slope reduction during a 12-month fol-
low-up period with monthly visits and a one-sided
alpha of 5% (24). Each scenario was simulated
25,000 times, which provides 99% accuracy in
determining the type 1 error (5%) of the analytical
strategies between 4.6% and 5.4% (5). In order to
facilitate the translation of empirical power to trial
design, we calculated sample sizes based on the
empirical power using the formula provided by
Healy and Schoenfeld (4). A detailed description of
the simulation, the model parameters and the source
code can be found at http://reactive.tricals.org.
Results
In total, our simulation model was based on
26,920 ALSFRS-R scores from 3412 patients; a
detailed description of the patient characteristics
can be found elsewhere (20). The observed rates
of decline for each subscale and the total score are
given in Table 2. If used in isolation, the total
score would require the smallest sample size or
achieve the highest power compared to its sub-
scales. In Table 3 we provide the empirical power
for various treatment efficacy scenarios of the total
score and the two alternative analytical strategies
(i.e. with or without a non-inferiority boundary).
Scenario I reflects a situation when treatment has
no effect and provides the type I error of each end-
point; all strategies adequately control type I error.
The value of the non-inferiority boundary is
illustrated in scenario II, which reflects a situation
with a motor and respiratory benefit of treatment,
but where treatment is harmful for bulbar func-
tioning. The alternative analytical strategy, without
non-inferiority boundary, would classify this treat-
ment in 73.0% of the simulations as effective
despite its potential harmful side-effects. An
important consideration is that in this scenario, on
average, there is an overall beneficial effect (i.e. a
10.6% slowing of the total score slope). As a con-
sequence, the total score considers this treatment
as effective, whereas the alternative analytical strat-
egy with non-inferiority boundary classifies it as
futile. Whether such a treatment is truly (in)effect-
ive might be debatable and such discussions could
help define values for -D at the design stage.
In terms of treatment benefit, a uniform scen-
ario, where treatment reduces all subscale slopes
identically by 25%, is best detected by the total
score (Table 3, scenario V). Nevertheless, the gain
in empirical power as compared to the alternative
analytical strategies is less than 5%. In case of non-
uniform subscale-specific treatment effects, utilizing
the alternative strategy may be a more powerful
approach. In scenario VI, for example, all subscales
respond, but one subscale responds more than the
others. Employing the alternative strategy increases
empirical power from 80.9% to 91.7%. In terms of
sample size, this means that a trial based on the
total score requires a sample size of 244 patients to
detect the treatment effect with 80% power, whereas
the alternative strategy requires only 174 patients
(–28.7%). Similarly, for a scenario based on the
recent trial with sodium phenylbutyrate–taururso-
diol, where treatment benefit was largest on the fine
motor subscale (25), power increases from 83.8% to
86.0%. In general, as the differences in treatment
responses between subscales increase, the more the
ALSFRS-R total score becomes affected (e.g. in
scenario III the total score requires 1380 patients vs.
336 (–75.7%) when utilizing the alternative strat-
egy). In the Supplementary results we illustrate the
mechanism that drives the loss of power of the total
score for non-uniform treatment scenarios.
Discussion
In this simulation study, we have evaluated the
performance of the ALSFRS-R total score for a
Table 2. Observed longitudinal model parameters of the subscales and total score.
Scale
Linear mixed model Trial design
Baseline (Intercept)
Rate of decline (Slope)
Sample size PowerSlope SD CoV
Total score 38.1 –1.06 0.82 0.77 248 80.0%
Bulbar 10.3 –0.22 0.25 1.14 524 53.7%
Fine motor 8.4 –0.34 0.27 0.79 270 77.2%
Gross motor 7.9 –0.31 0.24 0.77 258 78.8%
Respiratory 11.5 –0.19 0.25 1.32 788 40.5%
The table compares the monthly rate of decline, between-patient variability and estimated sample size.
Slope¼ coefficient for time in points per month; SD¼between-patient standard deviation of time (i.e., random slope
variability); CoV¼ coefficient of variation, calculated as the absolute value of SD/Estimate, a lower value indicates less
variation between patients in rates of decline. We provide per scale (1) the required sample size to detect a 25%
difference in slopes with 80% power and one-sided alpha of 5%, and (2) power to detect a 25% difference in slopes
given a fixed sample size of 248 for a 12-month study.
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variety of treatment efficacy scenarios. Our results
highlight the potential consequences of ignoring
the multidimensional structure of the total score in
clinical trials for ALS. The ALSFRS-R total score
may be insensitive to detecting treatment benefit
when a treatment affects only some of its sub-
scales, or benefits subscales in varying degrees,
resulting in potentially higher false-negative rates
and an increased risk of missing important treat-
ment clues. Implementing an alternative analytical
strategy that first assesses the subscale-specific
effects, prior to making a decision about whether a
treatment is generally effective, may circumvent
the pitfalls of the total score.
These results may not only have important
consequences for the design and analysis of future
trials, but may also question past observations.
One could hypothesize, for example, that the
absent riluzole effect on the ALSFRS-R total score
(26,27), despite the clear survival benefit (28),
may be driven by a non-uniform treatment effect
on one of the subscales (29). Unfortunately, sub-
scale-specific treatment effects are rarely reported
in ALS clinical trials and it is not known how
treatments have affected the ALSFRS-R subscales
in the past. The clinical trials with sodium phenyl-
butyrate–taurursodiol (25), Nuedexta and
Reldesemtiv (19,30), however, provide important
evidence that these non-uniform treatments do
exist and may dilute the treatment effect estimate
when quantified by the ALSFRS-R total score.
Given our results and the potential for non-uni-
form treatment effects in ALS clinical trials, we
recommend that the ALSFRS-R should no longer
only be reported as a total score. To address the
issues highlighted, it is necessary to account appro-
priately for the multidimensional structure of the
ALSFRS-R prior to making a definite statement
about treatment benefit. We evaluated a simple,
alternative testing strategy that can easily be imple-
mented in any statistical software package and
which will not affect the general conduct of a trial.
The non-inferiority boundary can be fine-tuned for
each subscale individually, or used more conserva-
tively when there is prior evidence of a potential
harmful side-effect. Moreover, it is important to
consider at the design stage which treatment
effects would still be considered effective. For
example, is a treatment that improves the total
score, but has detrimental consequences for one
of the subscales, still a valid treatment option
(Table 3, scenario II)? Or is a treatment that min-
imally improves the total score, but has some
beneficial effects on its subscales (Table 3, scen-
ario III) worthwhile? Answering these questions is
important in optimizing the proposed analytical
strategies and may require consensus discussions
with clinicians and patients.
In terms of trial design, if there is no a priori
knowledge of the treatment effect, sample size cal-
culation is straightforward and could be done by
conservatively assuming a uniform scenario.
Increasing the estimated sample size for the
ALSFRS-R total score by 12.5% provides identical
power for the alternative analytical strategy under
a uniform treatment scenario (Table 3) (4), while
having sufficient power to detect non-uniform
treatment effects. A minimum value for –D can
subsequently be calculated for each subscale indi-
vidually using the estimated sample size and
desired type 1 error level.
Our study has a few limitations that should be
considered. The multidimensional structure of the
ALSFRS-R makes the total score essentially a
composite endpoint (18). We evaluated a relatively
simple, assumption-free analytical strategy that
Table 3. Empirical power of the total score and two alternative analytical strategies.
Treatment efficacy scenario (Percentage slope reduction) Empirical power (N¼ 25,000 simulations)
No. Total Bulbar Fine Gross Resp. Total Alt. I Alt. II
No effect on total score
I 0.0% 0.0% 0.0% 0.0% 0.0% 0.054 0.045 0.045
Harmful subscale effect
II 10.6% – 43.5% 25.0% 25.0% 25.0% 0.288 0.730 0.051
Response on one or two subscales
III 8.4% 40.0% 0.0% 0.0% 0.0% 0.220 0.738 0.675
IV 16.9% 0.0% 27.5% 27.5% 0.0% 0.528 0.792 0.733
25% reduction in total score
V 25.0% 25.0% 25.0% 25.0% 25.0% 0.813 0.767 0.766
VI 25.0% 50.0% 18.4% 18.4% 18.4% 0.809 0.920 0.917
VII 25.0% 30.0% 20.4% 20.4% 35.0% 0.811 0.745 0.745
VIII 25.0% 30.4% 30.4% 30.4% 0.0% 0.809 0.889 0.843
Sodium Phenylbutyrate–Taurursodiol 25
IX 26.0% 25.7% 32.8% 21.1% 21.9% 0.838 0.861 0.860
Abbreviations: Resp. ¼ respiratory; Alt. I-II¼ alternative analytical strategy as depicted in Figure 2(B-C); No. ¼ Treatment efficacy
scenario, illustrated as the relative slope reduction in progression rate. For example, scenario II illustrates a 43.5% worsening in
bulbar slope and a 25.0% improvement in fine, gross and respiratory functioning. This results in a net improvement of the ALSFRS-R
total score slope of 10.6%.
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corrects solely for multiple testing. Nevertheless,
more complex alternatives could be considered,
such as defining a prospective testing hierarchy of
the subscales, applying a weighting scheme or
using multivariate mixed effects models
(18,31–33). These alternatives may further opti-
mize operational characteristics, but could increase
the complexity of the design or interpretation of
future clinical trials. Furthermore, there are several
definitions of ALSFRS-R subscales reported in lit-
erature (7,9,15,16,34), where fine and gross motor
function are either combined or taken separately.
This may affect the operational characteristics of
the alternative analytical strategy as using a com-
bined motor subscale would reduce the number of
tests and may improve statistical power. Given the
strong correlation between the fine and motor sub-
scales (Figure 1) (34), our power estimate of the
alternative analytical strategy might be too conser-
vative. More importantly, the operational charac-
teristics of the analytical strategies are primarily
driven by the ability of the subscales to detect the
treatment effect. Thus, improving the sensitivity of
the individual subscales may be an important tar-
get for future research. For example, replacing the
bulbar subscale by the Center for Neurological
Study Bulbar Function Scale (CNS-BFS) (35), or
the motor items by the Rasch-Built Overall ALS
Disability Scale (ROADS) (36), may further
increase the likelihood of detecting effective treat-
ments. In addition, new scales may reduce the
occurrence of plateaus and reversals due to a more
linear measurement scale and improved consist-
ency in scoring (e.g. preventing a false “reversal”
of ALSFRS-R item 2 when treating sialor-
rhea) (36–38).
Finally, combining survival time with the
ALSFRS-R has been shown to increase precision
or reduce sample size (3,5). It would be of interest
to extend the joint modeling framework, or similar
strategies, to a multivariable model in which each
subscale is modeled as covariate. Such a strategy
could potentially lead to additional efficiency gains,
but its application may be restricted to relatively
long studies that have sufficient information on
survival time. This limitation may be ameliorated
by making better use of adaptive strategies such as
seamless phase II to III designs. In these settings,
a decision could be based initially on accruing
ALSFRS-R subscale information, and, if there is
sufficient survival data, the decision process may
be shifted to the joint modeling framework. A
recent example of such an approach is the
STAMPEDE trial (39). Additional simulation
studies will be required to evaluate when such
approaches are indicated, with development of
appropriate methodology (40). This simultan-
eously underscores the need to continuously
update open-source databases such as PRO-ACT
in order to obtain representative simulation tools
for future studies.
In conclusion, in this simulation study, we
show that ignoring the multidimensional structure
of the ALSFRS-R total score could have poten-
tially negative consequences for ALS clinical trials.
We propose determining treatment benefit on a
subscale level, prior to stating whether a treatment
is generally effective. This strategy circumvents the
pitfalls of the total score and may increase the like-
lihood of finding an effective treatment for this
debilitating disease.
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